Vanadium in diabetes: 100 years from Phase 0 to Phase I

Thompson, Katherine H.; Orvig, Chris

doi:10.1016/j.jinorgbio.2006.08.016

Cited by 472 publications

(437 citation statements)

References 168 publications

(186 reference statements)

Supporting

Mentioning

423

Contrasting

Unclassified

Order By: Relevance

“…In particular, their potential insulin mimetic capacity has been extensively investigated [10][11][12][13][14][15][16]. It has been shown that VCs can be used to mitigate insufficient insulin response in DM thus presenting insulin-mimetic properties in vitro and [17][18][19][20] in vivo [21][22][23][24], and two of them were tested in clinical trials [25].…”

Section: Introductionmentioning

confidence: 99%

“…Among the many vanadium compounds reported in the literature, emphasis is given to the bis(matolato)oxidovanadium(IV) (BMOV) [11,14,37] and the similar one bis(ethylmaltolato) oxidovanadium(IV) (BEOV) [25], the only vanadium compounds tested in clinical trials to date, but other compounds like bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), [VO(dmpp) 2 ] [31,33,[36][37][38][39][40][41], bis(picolinato)oxidovanadium(IV) [VO(pic) 2 ] [24,42,43] and bis(allixinato)oxidovanadium(IV) [18,44,45] have also attracted much interest due to the positive results which have been obtained through in vitro and in vivo studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats

Domingues

Pelletier

Östenson

et al. 2014

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

The bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), VO(dmpp) 2 , has shown anti-diabetic effects by in vitro studies in Wistar (W) rat adipocytes and in vivo in obese Zucker rats. The aim of this work is to confirm the therapeutic properties of VO(dmpp) 2 in non-obese type 2 diabetic Goto-Kakizaki (GK) rats. An in vivo study was carried out, treating W and GK rats during 21 days with a daily dose of VO(dmpp) 2 (44 μmol/kg). It was shown that VO(dmpp) 2 doesn't affect the normal increase of body weight of both W and GK rats, after 8 days of treatment ameliorates glycemia in GK rats (8.4 ± 0.3 vs 10.1 ± 0.2 mM in GK control, P b 0.001) but doesn't interfere with glucose levels in W rats and, after 21 days of treatment, improves the glucose intolerant profile of GK rats (13.1 ± 0.5 vs 20.6 ± 0.7 mM/min in GK control, P b 0.001), despite no increase of plasma insulin levels during glucose tolerance test. Additionally, it was demonstrated that VO(dmpp) 2 significantly enhances [3-3 H]-glucose uptake by W and GK rat adipocytes (non-toxic concentration of 100 μM: respectively 193 ± 20 and 254 ± 21%, P b 0.001, relative to the basal value) showing an efficacy similar to insulin 1.72 nM and better than the same concentration of BMOV (P b 0.01). Western blotting revealed that in W and GK rats VO(dmpp) 2 significantly promotes IRS2 (P b 0.05) and p-AKT expression (P b 0.001 and P b 0.05, respectively, relative to the respective controls) and in GK animals reduces the increase of PTP1β expression (P b 0.001, relative to GK control).

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats

Domingues

Pelletier

Östenson

et al. 2014

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

show abstract

“…22) However, the V concentration in the hair samples from the diabetic subjects was similar to that in the control subjects (Table 2). Therefore, diabetes may not be related to a deficiency in V.…”

Section: Discussionmentioning

confidence: 58%

Essential and Non-essential Elements in Scalp Hair of Diabetics: Correlations with Glycated Hemoglobin (HbA1c)

Hotta

Fujino

Kimura

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Essential elements (Ca, Mg, Zn, Cu, Fe, Cr, Mn and V) and non-essential elements (As, Cd, Hg and Pb) were measured in scalp hair samples of 45 diabetic subjects and 59 control subjects in Japan using inductively coupled plasma mass spectrometry. All diabetic subjects took insulin and/or antidiabetic agents, with glycated hemoglobin (HbA1c) ranging between 6.2 and 14.4%. The levels of Zn, Cu and Cr in the diabetic subjects (HbA1c>7) were significantly lower than those in the control subjects (p<0.05), and these concentrations decreased significantly with increases in HbA1c (p<0.01). The levels of Fe and Mg in the diabetic subjects were insignificantly lower, and the concentration of Fe decreased significantly with increases in HbA1c (p<0.05) and the concentration of Mn tended to decrease (p<0.10). In contrast, the concentration of As tended to increase with increases in HbA1c ( p<0.10). The concentrations of other elements, such as Ca, Mn, V, Pb, Cd and Hg, in the diabetic subjects were similar to those of control subjects, and did not correlate with HbA1c. The average of estimated glomerular filtration rate (eGFR) in the diabetic subjects was 77.7 29.7 mL/min/1.73 m 2 with large variation (12.7-148 mL/min/1.73 m 2 ), and previous study reported the increase of urinary excretion of Zn, Cr, Mn and Mg in diabetic subjects. The decreases of Zn, Cu, Cr, Fe and Mg concentrations in hair may reflect increased urinary excretion of these elements due to diabetic nephropathy.Key words diabetes; scalp hair; glycated hemoglobin (HbA1c); zinc; chromium; copper Diabetes mellitus is a serious and chronic metabolic disorder. Type 2 diabetes results from a disruption in glucose metabolism associated with a reduction in insulin production and utilization by tissues. Glycated hemoglobin (HbA1c) levels are used for screening and diagnostic purposes as HbA1c indicates the quality of blood glucose control over the previous 1-2 or 2-3 months. A HbA1c (%) value greater than 6.5 is a cut-off point for diabetic subjects and is highly prognostic for longterm diabetes-related complications such as nephropathy, retinopathy and neuropathy, and maintenance of the HbA1c value below 7.0 is a therapeutic guideline for the prevention of such complications of the Japan Diabetic Society. Estimated glomerular filtration rate (eGFR) is used for screening for nephropathy. The glomerular filtration rate (GFR) generally decreases as diabetes progresses, but the early stage of diabetic nephropathy is characterized by hyperfiltration (increase of GFR). 1) Deficiencies in trace elements such as Cr, Zn, Cu, Mg and Mn have been shown to predispose a person to glucose tolerance and to promote the development of diabetic complications. 2,3) Insulin resistance (IR) is defined as the condition in which insulin sensitive tissues become numb to insulin reception, and a Cr deficiency can induce IR. 2) Zn is known to synthesize insulin as well as stabilize insulin that has been stored in the beta cells of the pancreas. 4) Further, Zn has an important role in the sec...

show abstract

“…33) Following this observation, the first human trial of VO(ema) 2 complex was reported in 2006. 34) Other interesting antidiabetic vanadyl complexes with different coordination environments, such as porphyrin complexes, thiazolethione complexes, hydroxydiazine-type complexes, furan complex, quercetin-related complexes, salen-related complexes, and dinuclear complexes, have recently been proposed. 14,[35][36][37] Zinc Type 2 insulin-resistant DM accounts for 95% of all DM.…”

Section: Vanadiummentioning

confidence: 99%

Overview and Frontier for the Development of Metallopharmaceutics

Sakurai

2010

JOURNAL OF HEALTH SCIENCE

View full text Add to dashboard Cite

This review introduces the development of metal-containing pharmaceutics (metallopharmaceutics) such as anticancer agents containing platinum (Pt) and ruthenium (Ru), and superoxide dismutase (SOD) mimetic, focusing on the recent topics on antidiabetic vanadium (V) and zinc (Zn) complexes as well as antioxidative copper (Cu) and Zn complexes. From the ancient ages, people used many types of inorganic compounds to treat physical disorders or diseases. Since the modern concept of chemotherapy was achieved by Paul Ehrlich, who developed the arsenic (As)-containing compound to treat syphilis in 1910, a wide variety of metallopharmaceutics have been proposed and clinically used worldwide. This review is described for the researchers who are interested in the current states for the development of metallopharmaceutics.

show abstract

Vanadium in diabetes: 100 years from Phase 0 to Phase I

Cited by 472 publications

References 168 publications

Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats

Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats

Essential and Non-essential Elements in Scalp Hair of Diabetics: Correlations with Glycated Hemoglobin (HbA1c)

Overview and Frontier for the Development of Metallopharmaceutics

Contact Info

Product

Resources

About